MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.
Our client was keen to explore ways in which patient access to their product could be accelerated in the UK.
They had heard of PIM and EAMS but were not sure if their product would qualify and whether the process would be a worthwhile investment of their time.
MAP was engaged to help understand whether this would be the right approach and to provide ongoing support if the client decided to proceed.
Confidential conversations with key stakeholders at MHRA, NICE and NHS England helped to assess feasibility and build support for our client’s PIM submission.
In parallel, we helped to pressure test the clients’ value proposition and work with them to ensure it was optimised for a PIM submission.
We provided support in preparing the PIM submission as well as engaging clinical experts to inform the response.
MAP managed to secure PIM designation for our client and support them to achieve full EAMS scientific opinion.
Our client’s product was brought to market in the UK eight months faster than would have been the case without pursuing PIM and EAMS.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52